| Autor: |
Genestreti G; Department of Medical Oncology, Isitiuto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy. g.genestreti@irst.emr.it, Giovannini N, Frizziero M, Maglie M, Sanna S, Cingarlini S, Molino AM, Piciucchi S, Cetto GL, Santo A |
| Jazyk: |
angličtina |
| Zdroj: |
Journal of chemotherapy (Florence, Italy) [J Chemother] 2011 Aug; Vol. 23 (4), pp. 232-7. |
| DOI: |
10.1179/joc.2011.23.4.232 |
| Abstrakt: |
We retrospectively evaluated elderly patients with advanced non-small cell lung cancer (NSCLC) treated with carboplatin (AUC 4-5) and gemcitabine (1,000-1,200 mg/m²). Thirty-six patients with performance Status (pS) 0-1 and median age 73 (range 70-78 years) were considered. Histology was squamous cell carcinoma (8 patients), adenocarcinoma (22) and NSCLC not otherwise specified (6). 149 cycles of chemotherapy were administered with a median of 3 per patient (range 3-6). Grade 3 non-hematologic toxicities were dyspnea (1 patient) and fever (1). Grade 3/4 hematologic toxicities were anemia (6), neutropenia (6) and thrombocytopenia (10), with dose reduction required in 13 patients. The overall disease control rate was 44.4%. We recorded no complete response, 8 partial response, 8 stable disease and 20 progressive disease. After a medium follow-up of 11 months, median progression- free survival and median survival were 5 and 11 months, respectively. Carboplatin and gemcitabine is a safe and active regimen in elderly advanced NSCLC patients with good PS. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
